Linda Petrone1, Teresa Chiacchio1, Valentina Vanini1, Elisa Petruccioli1, Gilda Cuzzi1, Cristina Di Giacomo2, Luigia Pucci2, Marzia Montalbano3, Raffaella Lionetti3, Angela Testa3, Daniele Lapa4, Assunta Navarra5, Ubaldo Visco-Comandini3, Delia Goletti6. 1. Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, 00149 Rome, Italy. 2. Clinical Biochemistry and Pharmacology Laboratory, INMI, Italy. 3. Infectious Diseases Hepatology Unit, POIT Department, INMI, Italy. 4. Department of Virology, INMI, Italy. 5. Department of Epidemiology and Preclinical Research, INMI, Italy. 6. Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, 00149 Rome, Italy. Electronic address: delia.goletti@inmi.it.
Abstract
OBJECTIVES: Independent of IL-28B polymorphisms, blood IP-10 is a promising biomarker for predicting therapy response in chronic HCV infection. Urine IP-10 has been proposed as a biomarker in tuberculosis, but to date, no urine biomarkers for HCV infection have been evaluated. In this cross-sectional study, we assessed whether IP-10 is detectable in the urine of chronically HCV-infected patients, and if so, whether urine IP-10 correlates with serum IP-10 and HCV-specific clinical parameters. METHODS: IP-10 was measured by ELISA in serum and urine concomitantly taken from 38 HCV-viremic patients, 10 cured-HCV subjects and 11 healthy donors enrolled as controls. RESULTS: The urine of HCV-viremic patients showed measurable amounts of IP-10, although significantly lower than in serum (p < 0.0001). Urine IP-10 was normalized with creatinuria levels and we found that the urine IP-10/creatinuria ratio was significantly higher in HCV-viremic patients than in cured-HCV subjects (p = 0.002) and healthy donors (p = 0.008), and that it significantly correlated with transaminases (p = 0.01), although the correlation was low. Similarly, the serum IP-10 level significantly associated with HCV-viremic patients (p < 0.0001) and correlated with transaminases (p < 0.0001). CONCLUSIONS: For the first time to our knowledge, we show that IP-10 is detected and increased in the urine of HCV-viremic patients compared to healthy donors and cured-HCV subjects.
OBJECTIVES: Independent of IL-28B polymorphisms, blood IP-10 is a promising biomarker for predicting therapy response in chronic HCV infection. Urine IP-10 has been proposed as a biomarker in tuberculosis, but to date, no urine biomarkers for HCV infection have been evaluated. In this cross-sectional study, we assessed whether IP-10 is detectable in the urine of chronically HCV-infectedpatients, and if so, whether urine IP-10 correlates with serum IP-10 and HCV-specific clinical parameters. METHODS:IP-10 was measured by ELISA in serum and urine concomitantly taken from 38 HCV-viremicpatients, 10 cured-HCV subjects and 11 healthy donors enrolled as controls. RESULTS: The urine of HCV-viremicpatients showed measurable amounts of IP-10, although significantly lower than in serum (p < 0.0001). Urine IP-10 was normalized with creatinuria levels and we found that the urine IP-10/creatinuria ratio was significantly higher in HCV-viremicpatients than in cured-HCV subjects (p = 0.002) and healthy donors (p = 0.008), and that it significantly correlated with transaminases (p = 0.01), although the correlation was low. Similarly, the serum IP-10 level significantly associated with HCV-viremicpatients (p < 0.0001) and correlated with transaminases (p < 0.0001). CONCLUSIONS: For the first time to our knowledge, we show that IP-10 is detected and increased in the urine of HCV-viremicpatients compared to healthy donors and cured-HCV subjects.
Authors: Agnieszka Strzelak; Anna Komorowska-Piotrowska; Katarzyna Krenke; Wioletta Zagórska; Witold Bartosiewicz; Wojciech Feleszko; Marek Kulus Journal: Diagnostics (Basel) Date: 2022-03-29
Authors: Linda Petrone; Angela Cannas; Francesco Aloi; Martin Nsubuga; Joseph Sserumkuma; Ritah Angella Nazziwa; Levan Jugheli; Tedson Lukindo; Enrico Girardi; Klaus Reither; Delia Goletti Journal: Biomed Res Int Date: 2015-08-05 Impact factor: 3.411
Authors: R M Ghanaiee; A Karimi; S M Hoseini-Alfatemi; J A Seddon; M Nasehi; P Tabarsi; S A Fahimzad; S Armin; J Akbarizadeh; E Rahimarbabi; L Azimi Journal: New Microbes New Infect Date: 2022-01-17
Authors: Prithwiraj De; Anita G Amin; Eloise Valli; Mark D Perkins; Michael McNeil; Delphi Chatterjee Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240